Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Spero Therapeutics (SPRO) EBIT Margin (2016 - 2025)

Spero Therapeutics' EBIT Margin history spans 10 years, with the latest figure at 66.79% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 3262448.0% year-over-year to 66.79%; the TTM value through Dec 2025 reached 9.0%, up 29639.0%, while the annual FY2025 figure was 13.42%, 1849483.0% up from the prior year.
  • EBIT Margin reached 66.79% in Q4 2025 per SPRO's latest filing, up from 145.46% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 221.04% in Q4 2021 to a low of 32557.69% in Q4 2024.
  • Average EBIT Margin over 5 years is 3080.04%, with a median of 258.29% recorded in 2025.
  • Peak YoY movement for EBIT Margin: surged 3534701bps in 2021, then crashed -3262918bps in 2024.
  • A 5-year view of EBIT Margin shows it stood at 221.04% in 2021, then dropped by -16bps to 184.73% in 2022, then tumbled by -61bps to 71.49% in 2023, then tumbled by -45641bps to 32557.69% in 2024, then surged by 100bps to 66.79% in 2025.
  • Per Business Quant, the three most recent readings for SPRO's EBIT Margin are 66.79% (Q4 2025), 145.46% (Q3 2025), and 20.71% (Q2 2025).